Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01681992
Recruitment Status : Completed
First Posted : September 10, 2012
Last Update Posted : November 30, 2016
Information provided by (Responsible Party):

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : February 2015
  Actual Study Completion Date : August 2015
  Certification/Extension First Submitted : April 7, 2016

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 December 30, 2016
(Canceled - Date Unknown)
January 16, 2017
(Canceled - Date Unknown)
February 9, 2017
(Canceled - Date Unknown)
March 21, 2017
April 28, 2017
2 August 17, 2017
September 14, 2017
3 December 5, 2017
January 4, 2018